Repeat laparoscopic hepatectomy versus radiofrequency ablation for recurrent hepatocellular carcinoma: A multicenter, propensity score matching analysis
BioScience Trends · 2024
DOI: 10.5582/bst.2024.01224 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BioScience Trends, 2024. Verfasst von Zihui Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, The Third Affiliated Hospital of Naval Military Medical University, Shangha…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatectomy, Laparoscopy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
This study aimed at analyzing and comparing the clinical efficacy and prognosis of repeat laparoscopic hepatectomy (r-LH) and radiofrequency ablation (RFA) in treating recurrent hepatocellular carcinoma (RHCC). Clinicopathological data of RHCC patients who underwent r-LH or RFA as treatment from three medical centers were retrospectively reviewed. Baseline characteristics at the recurrence time after initial hepatectomy and clinical outcomes following treatment of RHCC were compared between the two groups. Using the Kaplan-Meier method, survival curves for the two groups of patients were generated, and the log-rank test was used to compare survival differences. Propensity score matching (PSM) analysis was used to match patients of the r-LH and RFA groups in a 1:1 ratio. A total of 272 patients were enrolled, including 133 patients who underwent r-LH and 139 patients who received RFA. After PSM, 76 patients were matched in each study group. Compared with the r-LH group, the RFA group had shorter hospitalization and fewer postoperative complications. However, the r-LH group had significantly better overall survival (OS) and disease-free survival (DFS) than the RFA group before and after PSM. Subgroup analysis demonstrated that RHCC patients with solitary tumor or those with tumors located near the diaphragm, visceral surface or vessels, had survival benefits from r-LH. When tumor diameter ≤ 5 cm, r-LH appears to be an effective priority to RFA with a significantly higher OS and DFS rate in treating RHCC patients, especially for patients with solitary tumor and those with tumors located near the diaphragm, visceral surface or vessels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, The Third Affiliated Hospital of Naval Military Medical University, Shanghai, China.
- Department of Ultrasonic Intervention, Eastern Hepatobiliary Surgery Hospital, The Third Affiliated Hospital of Naval Military Medical University, Shanghai, China.
- Department of Hepatobiliary and Pancreatic Surgery, Xuzhou Municipal First People's Hospital, Xuzhou, China.
- Department of Hepatobiliary and Pancreatic Surgery, Fujian Provincial Hospital, The Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Zitieren
APA
Ma, Z., Lin, X., Zhang, J., Song, X., Yan, M., Guo, L., Xue, J., Lu, C., Shi, J., Cheng, S., & Guo, W. (2024). Repeat laparoscopic hepatectomy versus radiofrequency ablation for recurrent hepatocellular carcinoma: A multicenter, propensity score matching analysis. BioScience Trends. https://doi.org/10.5582/bst.2024.01224
Vancouver
Ma Z, Lin X, Zhang J, Song X, Yan M, Guo L, et al. Repeat laparoscopic hepatectomy versus radiofrequency ablation for recurrent hepatocellular carcinoma: A multicenter, propensity score matching analysis. BioScience Trends. 2024. doi:10.5582/bst.2024.01224
BibTeX
@article{Ma2024,
author = {Ma, Zihui and Lin, Xiaolu and Zhang, Jinglei and Song, Xingchao and Yan, Maolin and Guo, Lei and Xue, Jie and Lu, Chongde and Shi, Jie and Cheng, Shuqun and Guo, Weixing},
title = {Repeat laparoscopic hepatectomy versus radiofrequency ablation for recurrent hepatocellular carcinoma: A multicenter, propensity score matching analysis},
journal = {BioScience Trends},
year = {2024},
doi = {10.5582/bst.2024.01224}
}
EUVIMED